history of glp 1 agonists glucagon-like peptide-1 receptor Glucagon-like peptide-1 receptor: mechanisms and
Description
SUSTAIN-6 (Semaglutide in Subjects with Type 2 Diabetes) was the next trial published, lending credence to the cardiovascular benefits of semaglutide
Most patients tolerate this without symptoms, but those with underlying arrhythmias or cardiovascular disease should be monitored
Ultimately, careful monitoring, patient education, and individualized treatment plans are key
Stop taking your GLP-1 medication as soon as severe abdominal pain developsdo not wait for a scheduled appointment or attempt to manage symptoms at home with over-the-counter remedies
